Search

Your search keyword '"Araf, Shamzah"' showing total 127 results
Start Over Author "Araf, Shamzah"
127 results on '"Araf, Shamzah"'

1. Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

Author

Bewicke-Copley, Findlay, Korfi, Koorosh, Araf, Shamzah, Hodkinson, Brendan, Kumar, Emil, Cummin, Thomas, Ashton-Key, Margaret, Barrans, Sharon, van Hoppe, Suzan, Burton, Cathy, Elshiekh, Mohamed, Rule, Simon, Crosbie, Nicola, Clear, Andrew, Calaminici, Maria, Runge, Hendrik, Hills, Robert K., Scott, David W., Rimsza, Lisa M., Menon, Geetha, Sha, Chulin, Davies, John R., Nagano, Ai, Davies, Andrew, Painter, Daniel, Smith, Alexandra, Gribben, John, Naresh, Kikkeri N., Westhead, David R., Okosun, Jessica, Steele, Andrew, Hodson, Daniel J., Balasubramanian, Sriram, Johnson, Peter, Wang, Jun, and Fitzgibbon, Jude

Published
2023
Full Text
View/download PDF

2. Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR

Author

Ortega-Molina, Ana, Deleyto-Seldas, Nerea, Carreras, Joaquim, Sanz, Alba, Lebrero-Fernández, Cristina, Menéndez, Camino, Vandenberg, Andrew, Fernández-Ruiz, Beatriz, Marín-Arraiza, Leyre, de la Calle Arregui, Celia, Plata-Gómez, Ana Belén, Caleiras, Eduardo, de Martino, Alba, Martínez-Martín, Nuria, Troulé, Kevin, Piñeiro-Yáñez, Elena, Nakamura, Naoya, Araf, Shamzah, Victora, Gabriel D., Okosun, Jessica, Fitzgibbon, Jude, and Efeyan, Alejo

Published
2019
Full Text
View/download PDF

4. Disease evolution and outcomes in familial AML with germline CEBPA mutations

Author

Tawana, Kiran, Wang, Jun, Renneville, Aline, Bödör, Csaba, Hills, Robert, Loveday, Chey, Savic, Aleksandar, Van Delft, Frederik W., Treleaven, Jennifer, Georgiades, Panayiotis, Uglow, Elizabeth, Asou, Norio, Uike, Naokuni, Debeljak, Maruša, Jazbec, Janez, Ancliff, Philip, Gale, Rosemary, Thomas, Xavier, Mialou, Valerie, Döhner, Konstanze, Bullinger, Lars, Mueller, Beatrice, Pabst, Thomas, Stelljes, Matthias, Schlegelberger, Brigitte, Wozniak, Eva, Iqbal, Sameena, Okosun, Jessica, Araf, Shamzah, Frank, Anne-Katrine, Lauridsen, Felicia B., Porse, Bo, Nerlov, Claus, Owen, Carolyn, Dokal, Inderjeet, Gribben, John, Smith, Matthew, Preudhomme, Claude, Chelala, Claude, Cavenagh, Jamie, and Fitzgibbon, Jude

Published
2015
Full Text
View/download PDF

5. Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation

Author

Perrett, Megan, primary, Pickard, Lucy, additional, Kumar, Emil, additional, Palladino, Giuseppe, additional, Khan, Faraz, additional, Edmondson, Carina, additional, Knight, Connor, additional, Poynton, Edward, additional, Matthews, Janet, additional, Araf, Shamzah, additional, Clear, Andrew James, additional, Calaminici, Maria, additional, Gribben, John G., additional, King, Hamish, additional, Efremova, Mirjana, additional, Wang, Jun, additional, and Okosun, Jessica, additional

Published
2022
Full Text
View/download PDF

6. Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium

Author

Merron, Bridgin, Kazmi-Stokes, Shamim, Cummin, Thomas, Barrans, Sharon, Araf, Shamzah, Korfi, Koorosh, Pascua, Laura D Lopez, Caddy, Josh, Cozens, Kelly, Cucco, Francesco, Uddin, Rahman, Sha, Chulin, Tooze, Reuben, Griffiths, Gareth, Du, Ming Qing, Burton, Cathy, Westhead, David, Fitzgibbon, Jude, Schuh, Anna, Davies, Andrew, and Johnson, Peter

Published
2019
Full Text
View/download PDF

8. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

Author

Okosun, Jessica, Bödör, Csaba, Wang, Jun, Araf, Shamzah, Yang, Cheng-Yuan, Pan, Chenyi, Boller, Sören, Cittaro, Davide, Bozek, Monika, Iqbal, Sameena, Matthews, Janet, Wrench, David, Marzec, Jacek, Tawana, Kiran, Popov, Nikolay, O'Riain, Ciaran, O'Shea, Derville, Carlotti, Emanuela, Davies, Andrew, Lawrie, Charles H, Matolcsy, András, Calaminici, Maria, Norton, Andrew, Byers, Richard J, Mein, Charles, Stupka, Elia, Lister, T Andrew, Lenz, Georg, Montoto, Silvia, Gribben, John G, Fan, Yuhong, Grosschedl, Rudolf, Chelala, Claude, and Fitzgibbon, Jude

Published
2014
Full Text
View/download PDF

11. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Author

Heward, James, primary, Koniali, Lola, additional, D’Avola, Annalisa, additional, Close, Karina, additional, Yeomans, Alison, additional, Philpott, Martin, additional, Dunford, James, additional, Rahim, Tahrima, additional, Al Seraihi, Ahad F., additional, Wang, Jun, additional, Korfi, Koorosh, additional, Araf, Shamzah, additional, Iqbal, Sameena, additional, Bewicke-Copley, Findlay, additional, Kumar, Emil, additional, Barisic, Darko, additional, Calaminici, Maria, additional, Clear, Andrew, additional, Gribben, John, additional, Johnson, Peter, additional, Neve, Richard, additional, Cutillas, Pedro, additional, Okosun, Jessica, additional, Oppermann, Udo, additional, Melnick, Ari, additional, Packham, Graham, additional, and Fitzgibbon, Jude, additional

Published
2021
Full Text
View/download PDF

12. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Author

Heward, James A, primary, Konali, Lola, additional, D’Avola, Annalisa, additional, Close, Karina, additional, Yeomans, Alison, additional, Philpott, Martin, additional, Dunford, James, additional, Rahim, Tahrima, additional, Al Seraihi, Ahad F, additional, Wang, Jun, additional, Korfi, Koorosh, additional, Araf, Shamzah, additional, Iqbal, Sameena, additional, Bewicke-Copley, Findlay, additional, Kumar, Emil, additional, Barisic, Darko, additional, Calaminici, Maria, additional, Clear, Andrew, additional, Gribben, John, additional, Johnson, Peter, additional, Neve, Richard, additional, Okosun, Jessica, additional, Oppermann, Udo, additional, Melnick, Ari, additional, Packham, Graham, additional, and Fitzgibbon, Jude, additional

Published
2020
Full Text
View/download PDF

13. Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients

Author

Aries, James A., primary, Davies, Jeffrey K., additional, Auer, Rebecca L., additional, Hallam, Simon L., additional, Montoto, Silvia, additional, Smith, Matthew, additional, Sevillano, Belen, additional, Foggo, Vanessa, additional, Wrench, Bela, additional, Zegocki, Krzysztof, additional, Agrawal, Samir, additional, Le Dieu, Rifca, additional, Truelove, Edward, additional, Erblich, Thomas, additional, Araf, Shamzah, additional, Okosun, Jessica, additional, Oakervee, Heather, additional, Cavenagh, Jamie D., additional, Gribben, John G., additional, and Riches, John C., additional

Published
2020
Full Text
View/download PDF

14. Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma

Author

Araf, Shamzah, primary, Korfi, Koorosh, additional, Bewicke-Copley, Findlay, additional, Wang, Jun, additional, Cogliatti, Sergio, additional, Kumar, Emil, additional, Forrer, Flavio, additional, Barrington, Sally F., additional, Graham, Trevor A., additional, Scott, David W., additional, Rimsza, Lisa M., additional, Davies, Andrew, additional, Johnson, Peter, additional, Okosun, Jessica, additional, Fitzgibbon, Jude, additional, and Fehr, Martin, additional

Published
2020
Full Text
View/download PDF

16. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (vol 32, pg 1258, 2018)

Author

Araf, Shamzah, Wang, Jun, Korfi, Koorosh, Pangault, Celine, Kotsiou, Eleni, Rio-Machin, Ana, Rahim, Tahrima, Heward, James, Clear, Andrew, Iqbal, Sameena, Davies, Jeff K., Johnson, Peter, Calaminici, Maria, Montoto, Silvia, Auer, Rebecca, Chelala, Claude, Gribben, John G., Graham, Trevor A., Fest, Thierry, Fitzgibbon, Jude, Okosun, Jessica, Queen Mary University of London (QMUL), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

17. Oncogenic Rag GTPase signalling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR

Author

Ministerio de Ciencia, Innovación y Universidades (España), European Commission, Ministerio de Economía y Competitividad (España), Asociación Española Contra el Cáncer, Fundación Científica Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Fundación Vistare, L'Oréal-UNESCO For Women in Science, Cancer Research UK, Ortega-Molina, Ana, Deleyto-Seldas, Nerea, Carreras, Joaquim, Sanz, Alba, Lebrero-Fernández, Cristina, Menéndez, Camino, Vandenberg, Andrew, Fernández-Ruiz, Beatriz, Leyre Marín-Arraiza, Calle Arregui, Celia de la, Plata-Gómez, Ana Belén, Caleiras, Eduardo, Martino, Alba de, Martínez-Martín, Nuria, Troulé, Kevin, Piñeiro-Yáñez, Elena, Nakamura, Naoya, Araf, Shamzah, Victora, Gabriel D., Okosun, Jessica, Fitzgibbon, Jude, Efeyan, Alejo, Ministerio de Ciencia, Innovación y Universidades (España), European Commission, Ministerio de Economía y Competitividad (España), Asociación Española Contra el Cáncer, Fundación Científica Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Fundación Vistare, L'Oréal-UNESCO For Women in Science, Cancer Research UK, Ortega-Molina, Ana, Deleyto-Seldas, Nerea, Carreras, Joaquim, Sanz, Alba, Lebrero-Fernández, Cristina, Menéndez, Camino, Vandenberg, Andrew, Fernández-Ruiz, Beatriz, Leyre Marín-Arraiza, Calle Arregui, Celia de la, Plata-Gómez, Ana Belén, Caleiras, Eduardo, Martino, Alba de, Martínez-Martín, Nuria, Troulé, Kevin, Piñeiro-Yáñez, Elena, Nakamura, Naoya, Araf, Shamzah, Victora, Gabriel D., Okosun, Jessica, Fitzgibbon, Jude, and Efeyan, Alejo

Abstract

The humoral immune response requires that B cells undergo a sudden anabolic shift and high cellular nutrient levels, which are required to sustain the subsequent proliferative burst. Follicular lymphoma (FL) originates from B cells that have participated in the humoral response, and 15% of FL samples harbour point-activating mutations in RRAGC, an essential activator of mTORC1 downstream of the sensing of cellular nutrients. The impact of recurrent RRAGC mutations in B cell function and lymphoma is unexplored. RRAGC mutations, targeted to the endogenous locus in mice, confer a partial insensitivity to nutrient deprivation, but strongly exacerbate B cell responses and accelerate lymphomagenesis, while creating a selective vulnerability to pharmacological inhibition of mTORC1. This moderate increase in nutrient signalling synergizes with paracrine cues from the supportive T cell microenvironment that activate B cells via the PI3K–Akt–mTORC1 axis. Hence, Rragc mutations sustain induced germinal centres and murine and human FL in the presence of decreased T cell help. Our results support a model in which activating mutations in the nutrient signalling pathway foster lymphomagenesis by corrupting a nutrient-dependent control over paracrine signals from the T cell microenvironment.

Published
2019

18. Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Author

Bewicke-Copley, Findlay, primary, Korfi, Koorosh, additional, Araf, Shamzah, additional, Kumar, Emil Arjun, additional, Cummin, Thomas E C, additional, Ashton-Key, Margaret, additional, Barrans, Sharon, additional, Van Hoppe, Suzan, additional, Burton, Cathy, additional, Elshiekh, Mohamed, additional, Rule, Simon, additional, Crosbie, Nicola, additional, Clear, Andrew James, additional, Calaminici, Maria, additional, Scott, David W., additional, Rimsza, Lisa M., additional, Geetha, Menon, additional, Sha, Chulin, additional, Bentley, Michael A, additional, Nagano, Ai, additional, Davies, Andrew, additional, Painter, Daniel, additional, Smith, Alexandra, additional, Gribben, John G., additional, Naresh, Kikkeri, additional, Westhead, David R, additional, Okosun, Jessica, additional, Johnson, Peter, additional, Wang, Jun, additional, and Fitzgibbon, Jude, additional

Published
2019
Full Text
View/download PDF

19. Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Author

Jurinovic, Vindi, primary, Passerini, Verena, primary, Oestergaard, Mikkel Z, primary, Knapp, Andrea, primary, Mundt, Kirsten, primary, Araf, Shamzah, primary, Richter, Julia, primary, Fitzgibbon, Jude, primary, Klapper, Wolfram, primary, Marcus, Robert E., primary, Davies, Andrew, primary, Herold, Michael, primary, Hiddemann, Wolfgang, primary, Unterhalt, Michael, primary, Hoster, Eva, primary, and Weigert, Oliver, primary

Published
2019
Full Text
View/download PDF

20. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

Author

Araf, Shamzah, Wang, Jun, Korfi, Koorosh, Pangault, Celine, Kotsiou, Eleni, Rio-Machin, Ana, Rahim, Tahrima, Heward, James, Clear, Andrew, Iqbal, Sameena, Davies, Jeff K., Johnson, Peter, Calaminici, Maria, Montoto, Silvia, Auer, Rebecca, Chelala, Claude, Gribben, John G., Graham, Trevor A., Fest, Thierry, Fitzgibbon, Jude, Okosun, Jessica, Queen Mary University of London (QMUL), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Cancer Sciences Unit [Southampton, UK] (Cancer Research UK Centre), University of Southampton, Barts and the London Medical School, and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Spatio-Temporal Analysis, B-cell lymphoma, Gene Expression Profiling, Cancer genomics, Humans, Correction, [SDV.CAN]Life Sciences [q-bio]/Cancer, Genomics, Brief Communication, Lymphoma, Follicular, Cancer genetics, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

21. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2Dmutant lymphomas

Author

Heward, James, Konali, Lola, D'Avola, Annalisa, Close, Karina, Yeomans, Alison, Philpott, Martin, Dunford, James, Rahim, Tahrima, Al Seraihi, Ahad F., Wang, Jun, Korfi, Koorosh, Araf, Shamzah, Iqbal, Sameena, Bewicke-Copley, Findlay, Kumar, Emil, Barisic, Darko, Calaminici, Maria, Clear, Andrew, Gribben, John, Johnson, Peter, Neve, Richard, Cutillas, Pedro, Okosun, Jessica, Oppermann, Udo, Melnick, Ari, Packham, Graham, and Fitzgibbon, Jude

Abstract

Loss-of-function mutations in KMT2Dare a striking feature of germinal center (GC) lymphomas, resulting in decreased histone 3 lysine 4 (H3K4) methylation and altered gene expression. We hypothesized that inhibition of the KDM5 family, which demethylates H3K4me3/me2, would reestablish H3K4 methylation and restore the expression of genes repressed on loss of KMT2D.KDM5 inhibition increased H3K4me3 levels and caused an antiproliferative response in vitro, which was markedly greater in both endogenous and gene-edited KMT2Dmutant diffuse large B-cell lymphoma cell lines, whereas tumor growth was inhibited in KMT2Dmutant xenografts in vivo. KDM5 inhibition reactivated both KMT2D-dependent and -independent genes, resulting in diminished B-cell signaling and altered expression of B-cell lymphoma 2 (BCL2) family members, including BCL2 itself. KDM5 inhibition may offer an effective therapeutic strategy for ameliorating KMT2Dloss-of-function mutations in GC lymphomas.

Published
2021
Full Text
View/download PDF

23. Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant

Author

Araf, Shamzah, primary, Wang, Jun, additional, Ashton-Key, Margaret, additional, Korfi, Koorosh, additional, Di Bella, Doriana, additional, Rio-Machin, Ana, additional, Odabashian, Mariette, additional, Foria, Vipul, additional, Du, Ming-Qing, additional, Cucco, Francesco, additional, Barrans, Sharon, additional, Johnson, Peter, additional, Laird, Sophie R., additional, Fisher, Andrew M., additional, Cullis, Jonathan O., additional, Graham, Trevor A., additional, Okosun, Jessica, additional, Fitzgibbon, Jude, additional, and Chiecchio, Laura, additional

Published
2018
Full Text
View/download PDF

24. Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2-Mutated MDS/AML

Author

Al Seraihi, Ahad, primary, Rio-Machin, Ana, additional, Tawana, Kiran, additional, Bödör, Csaba, additional, Araf, Shamzah, additional, Heward, James A, additional, Smith, Matthew, additional, Iqbal, Sameena, additional, Best, Steven, additional, Lea, Nicholas, additional, McLornan, Donal, additional, Ellison, Alicia, additional, Tummala, Hemanth, additional, Romualdo Cardoso, Shirleny, additional, Cavenagh, Jamie D., additional, Vulliamy, Tom, additional, Dokal, Inderjeet, additional, and Fitzgibbon, Jude, additional

Published
2016
Full Text
View/download PDF

25. IGHVsequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution

Author

Odabashian, Mariette, Carlotti, Emanuela, Araf, Shamzah, Okosun, Jessica, Spada, Filomena, Gribben, John G., Forconi, Francesco, Stevenson, Freda K., Calaminici, Mariarita, and Krysov, Sergey

Abstract

Follicular lymphoma B cells undergo continuous somatic hypermutation (SHM) of their immunoglobulin variable region genes, generating a heterogeneous tumor population. SHM introduces DNA sequences encoding N-glycosylation sites asparagine-X-serine/threonine (N-gly sites) within the V-region that are rarely found in normal B-cell counterparts. Unique attached oligomannoses activate B-cell receptor signaling pathways after engagement with calcium-dependent lectins expressed by tissue macrophages. This novel interaction appears critical for tumor growth and survival. To elucidate the significance of N-gly site presence and loss during ongoing SHM, we tracked site behavior during tumor evolution and progression in a diverse group of patients through next-generation sequencing. A hierarchy of subclones was visualized through lineage trees based on SHM semblance between subclones and their discordance from the germline sequence. We observed conservation of N-gly sites in more than 96% of subclone populations within and across diagnostic, progression, and transformation events. Rare N-gly-negative subclones were lost or negligible from successive events, in contrast to N-gly-positive subclones, which could additionally migrate between anatomical sites. Ongoing SHM of the N-gly sites resulted in subclones with different amino acid compositions across disease events, yet the vast majority of resulting DNA sequences still encoded for an N-gly site. The selection and expansion of only N-gly-positive subclones is evidence of the tumor cells' dependence on sites, despite the changing genomic complexity as the disease progresses. N-gly sites were gained in the earliest identified lymphoma cells, indicating they are an early and stable event of pathogenesis. Targeting the inferred mannose-lectin interaction holds therapeutic promise.

Published
2020
Full Text
View/download PDF

26. EZH2 mutations are frequent and represent an early event in follicular lymphoma

Author

Bödör, Csaba, Grossmann, Vera, Popov, Nikolay, Okosun, Jessica, O'Riain, Ciarán, Tan, King, Marzec, Jacek, Araf, Shamzah, Wang, Jun, Lee, Abigail M., Clear, Andrew, Montoto, Silvia, Matthews, Janet, Iqbal, Sameena, Rajnai, Hajnalka, Rosenwald, Andreas, Ott, German, Campo, Elias, Rimsza, Lisa M., Smeland, Erlend B., Chan, Wing C., Braziel, Rita M., Staudt, Louis M., Wright, George, Lister, T. Andrew, Elemento, Olivier, Hills, Robert, Gribben, John G., Chelala, Claude, Matolcsy, András, Kohlmann, Alexander, Haferlach, Torsten, Gascoyne, Randy D., and Fitzgibbon, Jude

Published
2013
Full Text
View/download PDF

29. Erratum: Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

Author

Okosun, Jessica, primary, Wolfson, Rachel L, additional, Wang, Jun, additional, Araf, Shamzah, additional, Wilkins, Lucy, additional, Castellano, Brian M, additional, Escudero-Ibarz, Leire, additional, Seraihi, Ahad Fahad Al, additional, Richter, Julia, additional, Bernhart, Stephan H, additional, Efeyan, Alejo, additional, Iqbal, Sameena, additional, Matthews, Janet, additional, Clear, Andrew, additional, Guerra-Assunção, José Afonso, additional, Bödör, Csaba, additional, Quentmeier, Hilmar, additional, Mansbridge, Christopher, additional, Johnson, Peter, additional, Davies, Andrew, additional, Strefford, Jonathan C, additional, Packham, Graham, additional, Barrans, Sharon, additional, Jack, Andrew, additional, Du, Ming-Qing, additional, Calaminici, Maria, additional, Lister, T Andrew, additional, Auer, Rebecca, additional, Montoto, Silvia, additional, Gribben, John G, additional, Siebert, Reiner, additional, Chelala, Claude, additional, Zoncu, Roberto, additional, Sabatini, David M, additional, and Fitzgibbon, Jude, additional

Published
2016
Full Text
View/download PDF

31. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

Author

Okosun, Jessica, primary, Wolfson, Rachel L, additional, Wang, Jun, additional, Araf, Shamzah, additional, Wilkins, Lucy, additional, Castellano, Brian M, additional, Escudero-Ibarz, Leire, additional, Al Seraihi, Ahad Fahad, additional, Richter, Julia, additional, Bernhart, Stephan H, additional, Efeyan, Alejo, additional, Iqbal, Sameena, additional, Matthews, Janet, additional, Clear, Andrew, additional, Guerra-Assunção, José Afonso, additional, Bödör, Csaba, additional, Quentmeier, Hilmar, additional, Mansbridge, Christopher, additional, Johnson, Peter, additional, Davies, Andrew, additional, Strefford, Jonathan C, additional, Packham, Graham, additional, Barrans, Sharon, additional, Jack, Andrew, additional, Du, Ming-Qing, additional, Calaminici, Maria, additional, Lister, T Andrew, additional, Auer, Rebecca, additional, Montoto, Silvia, additional, Gribben, John G, additional, Siebert, Reiner, additional, Chelala, Claude, additional, Zoncu, Roberto, additional, Sabatini, David M, additional, and Fitzgibbon, Jude, additional

Published
2015
Full Text
View/download PDF

32. Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Author

Araf, Shamzah, Korfi, Koorosh, Nagano, Ai, Cummin, Thomas E C, Bentley, Michael, Thorner, Aaron R., Ashton-Key, Margaret, Calaminici, Maria, Clear, Andrew James, Davies, Andrew, Barrans, Sharon, Van Hoppe, Suzan, Burton, Cathy, Rule, Simon, Crosbie, Nicola, Painter, Daniel, Smith, Alexandra, Weinstock, David M., Westhead, David R, Okosun, Jessica, Gribben, John G., Johnson, Peter, and Fitzgibbon, Jude

Published
2017
Full Text
View/download PDF

34. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

Author

Okosun, Jessica, primary, Bödör, Csaba, additional, Wang, Jun, additional, Araf, Shamzah, additional, Yang, Cheng-Yuan, additional, Pan, Chenyi, additional, Boller, Sören, additional, Cittaro, Davide, additional, Bozek, Monika, additional, Iqbal, Sameena, additional, Matthews, Janet, additional, Wrench, David, additional, Marzec, Jacek, additional, Tawana, Kiran, additional, Popov, Nikolay, additional, O'Riain, Ciaran, additional, O'Shea, Derville, additional, Carlotti, Emanuela, additional, Davies, Andrew, additional, Lawrie, Charles H, additional, Matolcsy, András, additional, Calaminici, Maria, additional, Norton, Andrew, additional, Byers, Richard J, additional, Mein, Charles, additional, Stupka, Elia, additional, Lister, T Andrew, additional, Lenz, Georg, additional, Montoto, Silvia, additional, Gribben, John G, additional, Fan, Yuhong, additional, Grosschedl, Rudolf, additional, Chelala, Claude, additional, and Fitzgibbon, Jude, additional

Published
2013
Full Text
View/download PDF

37. Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma

Author

Okosun, Jessica, primary, Bödör, Csaba, additional, Wang, Jun, additional, Araf, Shamzah, additional, Marzec, Jacek, additional, Iqbal, Sameena, additional, Matthews, Janet, additional, Calaminici, Maria, additional, O'Riain, Ciaran, additional, O'Shea, Derville, additional, Carlotti, Emanuela, additional, Davies, Andrew, additional, Wrench, David, additional, Matolcsy, András, additional, Lister, T. Andrew, additional, Gribben, John G, additional, Montoto, Silvia, additional, Chelala, Claude, additional, and Fitzgibbon, Jude, additional

Published
2012
Full Text
View/download PDF

38. High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy

Author

Böodöor, Csaba, primary, Vera, Grossmann, additional, Kohlmann, Alexander, additional, Tan, King, additional, Okosun, Jessica, additional, Popov, Nikolay, additional, Araf, Shamzah, additional, Marzec, Jacek, additional, O‘Riain, Ciaran, additional, Lee, Abigail, additional, Clear, Andrew James, additional, Montoto, Silvia, additional, Matthews, Janet, additional, Iqbal, Sameena, additional, Rajnai, Hajnalka, additional, Rosenwald, Andreas, additional, Ott, German, additional, Campo, Elias, additional, Smeland, Erlend B., additional, Chan, Wing C., additional, Braziel, Rita M., additional, Staudt, Louis M., additional, Wright, George, additional, Rimsza, Lisa M., additional, Lister, T. Andrew, additional, Elemento, Olivier, additional, Gribben, John G, additional, Matolcsy, Andras, additional, Haferlach, Torsten, additional, Gascoyne, Randy D., additional, and Fitzgibbon, Jude, additional

Published
2012
Full Text
View/download PDF

39. Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis

Author

Tsitsikas, Dimitris A., primary, Morin, Amelie, additional, Araf, Shamzah, additional, Murtagh, Bernadine, additional, Johnson, Gemma, additional, Vinnicombe, Sarah, additional, Ellis, Stephen, additional, Suaris, Tamara, additional, Wilks, Mark, additional, Doffman, Sarah, additional, and Agrawal, Samir G., additional

Published
2012
Full Text
View/download PDF

41. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

Author

Okosun, Jessica, Wolfson, Rachel L, Wang, Jun, Araf, Shamzah, Wilkins, Lucy, Castellano, Brian M, Escudero-Ibarz, Leire, Al Seraihi, Ahad Fahad, Richter, Julia, Bernhart, Stephan H, Efeyan, Alejo, Iqbal, Sameena, Matthews, Janet, Clear, Andrew, Guerra-Assunção, José Afonso, Bödör, Csaba, Quentmeier, Hilmar, Mansbridge, Christopher, Johnson, Peter, Davies, Andrew, Strefford, Jonathan C, Packham, Graham, Barrans, Sharon, Jack, Andrew, Du, Ming-Qing, Calaminici, Maria, Lister, T Andrew, Auer, Rebecca, Montoto, Silvia, Gribben, John G, Siebert, Reiner, Chelala, Claude, Zoncu, Roberto, Sabatini, David M, and Fitzgibbon, Jude

Abstract

Follicular lymphoma is an incurable B cell malignancy characterized by the t(14;18) translocation and mutations affecting the epigenome. Although frequent gene mutations in key signaling pathways, including JAK-STAT, NOTCH and NF-κB, have also been defined, the spectrum of these mutations typically overlaps with that in the closely related diffuse large B cell lymphoma (DLBCL). Using a combination of discovery exome and extended targeted sequencing, we identified recurrent somatic mutations in RRAGC uniquely enriched in patients with follicular lymphoma (17%). More than half of the mutations preferentially co-occurred with mutations in ATP6V1B2 and ATP6AP1, which encode components of the vacuolar H+-ATP ATPase (V-ATPase) known to be necessary for amino acid−induced activation of mTORC1. The RagC variants increased raptor binding while rendering mTORC1 signaling resistant to amino acid deprivation. The activating nature of the RRAGC mutations, their existence in the dominant clone and their stability during disease progression support their potential as an excellent candidate for therapeutic targeting.

Published
2016
Full Text
View/download PDF

42. The use of interim 18F-fluorodeoxyglucose PET to guide therapy in lymphoma.

Author

Araf, Shamzah and Montoto, Silvia

Abstract

Over the past decade 18F-fluorodeoxyglucose (FDG) -PET combined with computed tomography has gained a central role in the management of patients with lymphoma. The use of FDG-PET for staging and assessing treatment response in Hodgkin's and 'aggressive' non-Hodgkin's lymphoma is now well established, and the prognostic impact of the response to treatment assessed by FDG-PET is being increasingly recognized. Despite the widespread utilization of FDG-PET in clinical practice, key questions remain on its optimal use in certain contexts. One such area that is generating intense interest is the role of interim FDG-PET (typically performed after two to four cycles of chemotherapy) to guide treatment strategies. The author's will review the current available evidence in this area, highlighting questions in need of further study. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

43. Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey.

Author

Freeman, Tanya, Johnstone, Peter, Hibbs, Stephen P., Assefa, Esubalew, Araf, Shamzah, Farren, Timothy, and Butler, Tom

Subjects
*BLOOD cell count, *CLONE cells, *ASYMPTOMATIC patients, *LYMPHOCYTE count, *LYMPHOCYTOSIS
Abstract

ABSTRACT Asymptomatic lymphocytosis poses a common challenge in haematology. Immunophenotyping can establish whether a clonal population is present, but it is expensive and the benefit of diagnosing asymptomatic patients is unproven. This study aimed to establish data to guide the use of immunophenotyping. We analysed the proportion of lymphocytosis in full blood count (FBC) samples across a five‐year period within a large UK National Health Service (NHS) trust. Persistent lymphocytosis was present in 0.18% (437/242678) of repeat community samples. Of samples sent for immunophenotyping, 743/784 (95%) with a lymphocyte count > 10 × 109/L had a clonal population, compared to 223/1696 (14%) with a lymphocyte count < 5 × 109/L. We followed up a longitudinal cohort of asymptomatic patients with clonal lymphocytosis to determine how many required treatment. The minority (11/46) of patients needed treatment within 9 years of follow‐up. Of patients needing treatment, 10/11 (91%) had a presenting lymphocyte count > 10 × 109/L. In all cases, treatment was initiated when the patient became symptomatic. We propose a lymphocyte count threshold of > 10 × 109/L for referral and immunophenotyping in patients with asymptomatic lymphocytosis. This approach aims to balance safety and cost‐effectiveness and reflects uncertainty in the value of diagnosis for asymptomatic patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. EZH2mutations are frequent and represent an early event in follicular lymphoma

Author

Bödör, Csaba, Grossmann, Vera, Popov, Nikolay, Okosun, Jessica, O'Riain, Ciarán, Tan, King, Marzec, Jacek, Araf, Shamzah, Wang, Jun, Lee, Abigail M., Clear, Andrew, Montoto, Silvia, Matthews, Janet, Iqbal, Sameena, Rajnai, Hajnalka, Rosenwald, Andreas, Ott, German, Campo, Elias, Rimsza, Lisa M., Smeland, Erlend B., Chan, Wing C., Braziel, Rita M., Staudt, Louis M., Wright, George, Lister, T. Andrew, Elemento, Olivier, Hills, Robert, Gribben, John G., Chelala, Claude, Matolcsy, András, Kohlmann, Alexander, Haferlach, Torsten, Gascoyne, Randy D., and Fitzgibbon, Jude

Abstract

Gain of function mutations in the H3K27 methyltransferase EZH2 represent a promising therapeutic target in germinal center lymphomas. In this study, we assessed the frequency and distribution of EZH2mutations in a large cohort of patients with follicular lymphoma (FL) (n = 366) and performed a longitudinal analysis of mutation during the disease progression from FL to transformed FL (tFL) (n = 33). Mutations were detected at 3 recurrent mutation hot spots (Y646, A682, and A692) in 27% of FL cases with variant allele frequencies (VAF) ranging from 2% to 61%. By comparing VAF of EZH2with other mutation targets (CREBBP, MLL2, TNFRSF14, and MEF2B), we were able to distinguish patients harboring clonal EZH2mutation from rarer cases with subclonal mutations. Overall, the high incidence of EZH2mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZH2 targeted therapy.

Published
2013
Full Text
View/download PDF

45. An unusual cause of a haemorrhagic stroke:acquired haemophilia A.

Author

Araf, Shamzah, Aleem, Sobia, Liu, Boyang, and Balikai, Girish

Subjects
HEMOPHILIA complications, BLOOD coagulation factors, STROKE, PARTIAL thromboplastin time
Abstract

An elderly woman presented with extensive bruising and a haemorrhagic stroke. Initial investigations revealed an abnormal clotting screen with a prolonged activated partial thromboplastin time. Further investigations revealed this to be due to antibodies that the patient had developed against clotting factor VIII also known as acquired haemophilia A. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

47. Clinical and laboratory characteristics of acute myeloid leukaemia (AML) at relapse and the risk of acute incapacitation.

Author

Chapman, Michael Spencer, Araf, Shamzah, and Smith, Matthew

Subjects
*ACUTE myeloid leukemia, *LEUKEMIA diagnosis, *DISEASE relapse, *BRUISES, *PHYSIOLOGY, *PATIENTS, HEALTH of patients
Abstract

The article presents the study on the clinical and laboratory characteristics of patients with relapsed acute myeloid leukaemia (AML). It states that fifty percent of patients were asymptomatic and thirty-five percent had mild symptoms of anaemia or easy bruising. It mentions that the AML relapse tends to be related with no or mild symptoms.

Published
2016
Full Text
View/download PDF

48. Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Author

Jurinovic, Vindi, Passerini, Verena, Oestergaard, Mikkel Z, Knapp, Andrea, Mundt, Kirsten, Araf, Shamzah, Richter, Julia, Fitzgibbon, Jude, Klapper, Wolfram, Marcus, Robert E., Davies, Andrew, Herold, Michael, Hiddemann, Wolfgang, Unterhalt, Michael, Hoster, Eva, and Weigert, Oliver

Abstract

Introduction:We have previously shown that a clinicogenetic risk model called the m7-Follicular Lymphoma (FL) International Prognostic Index (m7-FLIPI), which includes the mutation status of 7 genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11), the FLIPI, and the ECOG performance status improves risk stratification in patients with advanced stage FL receiving frontline immunochemotherapy (Pastore, 2015). The m7-FLIPI was trained on a group of patients treated with R-CHOP and validated on an independent cohort treated with R-CVP. The aim of this study was to test the prognostic utility of the m7-FLIPI in patients treated within the GALLIUM trial.

Published
2019
Full Text
View/download PDF

49. Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

Author

Okosun, Jessica, Wolfson, Rachel L, Wang, Jun, Araf, Shamzah, Wilkins, Lucy, Castellano, Brian M, Escudero-Ibarz, Leire, Seraihi, Ahad Fahad Al, Richter, Julia, Bernhart, Stephan H, Efeyan, Alejo, Iqbal, Sameena, Matthews, Janet, Clear, Andrew, Guerra-Assunção, José Afonso, Bödör, Csaba, Quentmeier, Hilmar, Mansbridge, Christopher, Johnson, Peter, Davies, Andrew, Strefford, Jonathan C, Packham, Graham, Barrans, Sharon, Jack, Andrew, Du, Ming-Qing, Calaminici, Maria, Lister, T Andrew, Auer, Rebecca, Montoto, Silvia, Gribben, John G, Siebert, Reiner, Chelala, Claude, Zoncu, Roberto, Sabatini, David M, and Fitzgibbon, Jude

Published
2016
Full Text
View/download PDF

50. High Incidence of EZH2Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy

Author

Böodöor, Csaba, Vera, Grossmann, Kohlmann, Alexander, Tan, King, Okosun, Jessica, Popov, Nikolay, Araf, Shamzah, Marzec, Jacek, O‘Riain, Ciaran, Lee, Abigail, Clear, Andrew James, Montoto, Silvia, Matthews, Janet, Iqbal, Sameena, Rajnai, Hajnalka, Rosenwald, Andreas, Ott, German, Campo, Elias, Smeland, Erlend B., Chan, Wing C., Braziel, Rita M., Staudt, Louis M., Wright, George, Rimsza, Lisa M., Lister, T. Andrew, Elemento, Olivier, Gribben, John G, Matolcsy, Andras, Haferlach, Torsten, Gascoyne, Randy D., and Fitzgibbon, Jude

Abstract

Abstract 545

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results